First-line CDK 4/6 inhibition shows overall survival benefit for metastatic breast cancer
Despite high prevalence, urinary incontinence is still very much a taboo
20 September 2021New method used to study how cancer cells are organised
20 September 2021First-line CDK 4/6 inhibition shows overall survival benefit for metastatic breast cancer
Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative advanced breast cancer, according to late breaking results of the MONALEESA-2 trial presented at the ESMO Congress 2021.
